aser therapy in treatment of Trigger Finger and De Quervains

Not Applicable

Completed

• Conditions: Musculoskeletal Diseases; Trigger finger disease, De Quervains tenosynovitis; Trigger finger, Radial styloid tenosynovitis [de Quervain]

• Registration Number: ISRCTN85358156
• Lead Sponsor: Guy's & St Thomas' NHS Foundation Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-04-12
• Last Update Posted: 6 February 2017

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

We have 3 separate cohorts in our study:

1. Cohort 1 ? Trigger Finger - all adults, either sex, aged 18 and over with single or multiple digit trigger finger disease.

2. Cohort 2 ? Trigger finger in diabetics with bilateral disease- all adults, either sex, aged 18 and over with symmetrical bilateral trigger finger(s) and a diagnosis of diabetes mellitus.

3. Cohort 3 ? De Quervains - all adults, either sex, aged 18 and over with De Quervains tenosynovitis.

Exclusion Criteria

Cohort 1:
1. Under 18 years
2. Those with a diagnosis of diabetes mellitus
3. All patients with a diagnosis of any form of cancer
4. Any patient >65 years old
5. With mini?mental state examination (MMSE) <21

Cohort 2:
1. Under 18 years
2. All patients with a diagnosis of any form of cancer
3. Any patient >65 years old
4. With MMSE <21

Cohort 3:
1. Under 18 years
2. All patients with a diagnosis of any form of cancer
3. Any patient >65 years old
3. With MMSE <21

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Does high intensity laser therapy reduce symptoms of finger locking and pain in trigger finger disease (a condition where finger tendons can inflammed and become locked in a flexed/bent position facing the palm), and does it reduce pain and improve strength in de quervains disease (inflammed tendons of the thumb).

Secondary Outcome Measures

Name	Time	Method
1. The number of laser treatments sufficient to treat trigger finger disease and de quervains<br>2. The number of complications prevented by treating patients with laser therapy versus splinting<br>3. The cost effectiveness of treating patients with laser therapy versus splinting